Advertisement
| antibody engineering and therapeutics conference: Antibody Engineering J. Donald Capra, 1997 The last decade has witnessed remarkable developments in antibody research and its therapeutic applications. With the methods of molecular biology it is now possible to manipulate the specificities and activities of antibody molecules to generate an almost limitless array of structures for both basic investigations and the clinical setting. The contributions to this volume cover all three domains of the antibody: the variable regions, the relatively neglected but crucial hinge, and the constant region. These studies provide critical structural and functional information about antibodies, while also pointing the way to the construction of molecules with enhanced or even novel properties. Bringing together major experts on antibody engineering, this book is highly recommended to faculty, postdoctoral fellows and graduate students in molecular biology, microbiology, immunology, cancer research and genetics. |
| antibody engineering and therapeutics conference: Introduction to Antibody Engineering Florian Rüker, Gordana Wozniak-Knopp, 2021-01-04 This highly readable textbook serves as a concise and engaging primer to the emerging field of antibody engineering and its various applications. It introduces readers to the basic science and molecular structure of antibodies, and explores how to characterize and engineer them. Readers will find an overview of the latest methods in antibody identification, improvement and biochemical engineering. Furthermore, alternative antibody formats and bispecific antibodies are discussed. The book’s content is based on lectures for the specializations “Protein Engineering” and “Medical Biotechnology” within the Master’s curriculum in “Biotechnology.” The lectures have been held at the University of Natural Resources and Life Sciences, Vienna, in cooperation with the Medical University of Vienna, since 2012 and are continuously adapted to reflect the latest developments in the field. The book addresses Master’s and PhD students in biotechnology, molecular biology and immunology, and all those who are interested in antibody engineering. |
| antibody engineering and therapeutics conference: Structure and Function of Antibodies Roy Jefferis, Koichi Kato, William R. (Bill) Strohl, 2021-02-05 This book provides a detailed description of all kinds of therapeutic antibodies including IgGs, IgAs, IgEs, and IgMs, bispecific antibodies, chimeric antigen receptor antibodies, and antibody fragments. Details about how each of these antibodies interact with their ligands, the immune system, and their targets are provided. Additionally, this book delves into the details of antibody, Fc, and variable chain structures, and how subtle changes in structure, charge, flexibility, post-translational modification, and the ability to bind to natural antibody ligands can result in a significant impact on antibody activity and functionality. Finally, the book explains the critical quality attributes of modern therapeutic antibodies and how to ensure that antibodies entering development have the best possible chance of success. |
| antibody engineering and therapeutics conference: Immunoinformatics Christian Schönbach, Shoba Ranganathan, Vladimir Brusic, 2007-11-21 In contrast to existing books on immunoinformatics, this volume presents a cross-section of immunoinformatics research. The contributions highlight the interdisciplinary nature of the field and how collaborative efforts among bioinformaticians and bench scientists result in innovative strategies for understanding the immune system. Immunoinformatics is ideal for scientists and students in immunology, bioinformatics, microbiology, and many other disciplines. |
| antibody engineering and therapeutics conference: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| antibody engineering and therapeutics conference: Innovations for Next-Generation Antibody-Drug Conjugates Marc Damelin, 2018-05-29 Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients. |
| antibody engineering and therapeutics conference: Catalytic Antibodies Sudhir Paul, 2000-01-01 This volume addresses fundamental questions concerning the immunological genesis of the catalytic activity in antibodies, its relationship with classical antigen binding activity, and the biochemical mechanisms involved in catalysis. The contents reflect three main challenges in the field, i.e. to delineate the biological functions of catalytic antibodies in autoimmune disease; to isolate therapy-grade antibody catalysts with sufficient specificity and turnover to permit rapid removal of microbial and tumor antigens; and to develop immunogens that recruit immature catalyst-producing B cells into the clonal selection pathway and induce adaptive improvements of the catalytic function. Well-edited and up-to-date, this book reviews the current knowledge in the field and explores ways by which natural and engineered catalytic activities can be harnessed for medical applications. It should therefore be of special interest to immunologists, biochemists, biotechnologists, rheumatologists and pathologists. |
| antibody engineering and therapeutics conference: Cytotoxic Payloads for Antibody–Drug Conjugates David E Thurston, Paul J M Jackson, 2019-07-11 Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (KadcylaTM), brentuximab vedotin (AdcetrisTM), inotuzumab ozogamicin (BesponsaTM), gemtuzumab ozogamicin (MylotargTM) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future. |
| antibody engineering and therapeutics conference: The Business of Healthcare Innovation Lawton Robert Burns, 2005-08-25 The Business of Healthcare Innovation is the first wide-ranging analysis of business trends in the manufacturing segment of the health care industry. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. Written by professors of the Wharton School and industry executives, this book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. It analyses the market structures of these sectors as well as the business models and corporate strategies of firms operating within them. Most importantly, the book describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others. It will be essential reading for students and researchers in the field of health management, and of great interest to strategy scholars, industry practitioners and management consultants. |
| antibody engineering and therapeutics conference: 8th European Medical and Biological Engineering Conference Tomaz Jarm, Aleksandra Cvetkoska, Samo Mahnič-Kalamiza, Damijan Miklavcic, 2020-11-29 This book aims at informing on new trends, challenges and solutions, in the multidisciplinary field of biomedical engineering. It covers traditional biomedical engineering topics, as well as innovative applications such as artificial intelligence in health care, tissue engineering , neurotechnology and wearable devices. Further topics include mobile health and electroporation-based technologies, as well as new treatments in medicine. Gathering the proceedings of the 8th European Medical and Biological Engineering Conference (EMBEC 2020), held on November 29 - December 3, 2020, in Portorož, Slovenia, this book bridges fundamental and clinically-oriented research, emphasizing the role of education, translational research and commercialization of new ideas in biomedical engineering. It aims at inspiring and fostering communication and collaboration between engineers, physicists, biologists, physicians and other professionals dealing with cutting-edge themes in and advanced technologies serving the broad field of biomedical engineering. |
| antibody engineering and therapeutics conference: IgY-Technology: Production and Application of Egg Yolk Antibodies Xiao-Ying Zhang, Ricardo S. Vieira-Pires, Patricia M. Morgan, Rüdiger Schade, 2021-06-25 This first edited Volume on IgY-Technology, addresses the historical and dynamic development of IgY-applications. The authors cover the biological basis and theoretical context, methodological guidance, and applications of IgY-Technology. A focus is laid on the use of IgY-antibodies for prophylactic/therapeutic purposes in human and veterinary medicine. Aside from applications, the chapters also offer an evolutionary understanding of the IgY molecule, IgY receptors and practical prerequisites to produce IgY-antibodies. Guidance is given for every step of the process. Starting with an introduction to hens as a model species and including hen husbandry, hen egg-laying capacity and total IgY outcomes. Readers will also learn about immunization techniques, the advantages and limitations of different IgY extraction methods, as well as storage stability of the final product. The last part of the volume highlights hands-on aspects of applications, such as IgY delivery strategies, new methods to produce monoclonal IgY-antibodies or production of functional IgY fragments by phage-display as well as commercial exploitation of the technology. Thus, this book is a valuable resource and guide for Scientists, Clinicians and Health Product Developers in both human and veterinary medicine. |
| antibody engineering and therapeutics conference: Process Scale Purification of Antibodies Uwe Gottschalk, 2017-03-07 Promoting a continued and much-needed renaissance in biopharmaceutical manufacturing, this book covers the different strategies and assembles top-tier technology experts to address the challenges of antibody purification. • Updates existing topics and adds new ones that include purification of antibodies produced in novel production systems, novel separation technologies, novel antibody formats and alternative scaffolds, and strategies for ton-scale manufacturing • Presents new and updated discussions of different purification technologies, focusing on how they can address the capacity crunch in antibody purification • Emphasizes antibodies and innovative chromatography methods for processing |
| antibody engineering and therapeutics conference: Antibody Engineering Volume 2 Roland E. Kontermann, Stefan Dübel, 2010-03-10 Antibodies are indispensable tools for research, diagnosis, and therapy. Recombinant approaches allow the modification and improvement of nearly all antibody properties, such as affinity, valency, specificity, stability, serum half-life, effector functions, and immunogenicity. Antibody Engineering provides a comprehensive toolbox covering the well-established basics but also many exciting new techniques. The protocols reflect the latest hands on knowledge of key laboratories in this still fast-moving field. Newcomers will benefit from the proven step-by-step protocols, which include helpful practical advice; experienced antibody engineers will appreciate the new ideas and approaches. The book is an invaluable resource for all those engaged in antibody research and development. |
| antibody engineering and therapeutics conference: Antibody Engineering Carl A. K. Borrebaeck, 1995 In presenting a practical overview of the engineering of recombinant human or mouse monoclonal antibodies, the book incisively addresses essential topics such as antibody structure relevant to engineering, recombinatorial cDNA libraries, phage display, synthetic and humanized antibodies, engineering of affinity and biological effector functions, and plant, mammalian, and bacterial expression vectors and hosts. Antibody Engineering, Second Edition - written by leading experts and now thoroughly updated - is a unique resource for current information on the subject. |
| antibody engineering and therapeutics conference: Therapeutic Monoclonal Antibodies Zhiqiang An, 2011-09-20 70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. First book to address the discovery and development of antibody therapeutics in their entirety. Most chapters contain experimental data to illustrate the principles described in them. Authors provide detailed methodologies that readers can take away with them and use in their own laboratories. |
| antibody engineering and therapeutics conference: Monoclonal Antibody-Directed Therapy Veysel Kayser, Amita Datta-Mannan, 2022-01-28 The book deals with therapeutic monoclonal antibodies (mAbs) broadly, and relevant topics such as challenges and opportunities, next-generation antibody products, Antibody-Drug-Conjugates (ADC), bispecifics, glycosylation, and T-cell engagers are covered. Each topic has been written by leading groups around the world and the book should be of interest to researchers from both academia and industry. |
| antibody engineering and therapeutics conference: Digital Pathology Liron Pantanowitz, Anil V. Parwani, 2017 The definitive, complete reference of digital pathology! An extraordinarily comprehensive and complete book for individuals with anything from minimal knowledge to deep, accomplished experience in digital pathology. Easy to read and plainly written, Digital Pathology examines the history and technological evolution of digital pathology, from the birth of scanning technology and telepathology to three-dimensional imaging on large multi-touch displays and computer aided diagnosis. A must-have book for anyone wishing to learn more about and work in this exciting and critical information environment including pathologists, laboratory professionals, students and any other medical practitioners with a particular interest in the history and future of digital pathology. It can also be a useful reference for anyone, medical or non-medical, who have an interest in learning more about the field. Digital pathology is truly a game changer, and this book is a crucial tool for anyone wishing to know more. Subjects discussed in depth include: Static digital imaging; basics and clinical use. Digital imaging processes. Telepathology. While slide imaging. Clinical applications of whole slide imaging. Digital pathology for educational, quality improvement, research and other settings. Forensic digital imaging. |
| antibody engineering and therapeutics conference: Respiratory Drug Delivery (1989) Peter R. Byron, 2018-04-20 The focus of this book is on subjects related to drug delivery to the lung. The text spans topics from aerosol deposition through pharmaceutical chemistry and formulation to the final clinical evaluation of pharmaceutical products. Utilizing a multi-disciplinary approach, the chapters consider toxicology from the point of view of drugs and pharmaceutical excipients used in aerosols. |
| antibody engineering and therapeutics conference: Bugs as Drugs Robert A. Britton, Patrice D. Cani, 2018-02-01 Examining the enormous potential of microbiome manipulation to improve health Associations between the composition of the intestinal microbiome and many human diseases, including inflammatory bowel disease, cardiovascular disease, metabolic disorders, and cancer, have been elegantly described in the past decade. Now, whole-genome sequencing, bioinformatics, and precision gene-editing techniques are being combined with centuries-old therapies, such as fecal microbiota transplantation, to translate current research into new diagnostics and therapeutics to treat complex diseases. Bugs as Drugs provides a much-needed overview of microbes in therapies and will serve as an excellent resource for scientists and clinicians as they carry out research and clinical studies on investigating the roles the microbiota plays in health and disease. In Bugs as Drugs, editors Robert A. Britton and Patrice D. Cani have assembled a fascinating collection of reviews that chart the history, current efforts, and future prospects of using microorganisms to fight disease and improve health. Sections cover traditional uses of probiotics, next-generation microbial therapeutics, controlling infectious diseases, and indirect strategies for manipulating the host microbiome. Topics presented include: How well-established probiotics support and improve host health by improving the composition of the intestinal microbiota of the host and by modulating the host immune response. The use of gene editing and recombinant DNA techniques to create tailored probiotics and to characterize next-generation beneficial microbes. For example, engineering that improves the anti-inflammatory profile of probiotics can reduce the number of colonic polyps formed, and lactobacilli can be transformed into targeted delivery systems carrying therapeutic proteins or bioengineered bacteriophage. The association of specific microbiota composition with colorectal cancer, liver diseases, osteoporosis, and inflammatory bowel disease. The gut microbiota has been proposed to serve as an organ involved in regulation of inflammation, immune function, and energy homeostasis. Fecal microbiota transplantation as a promising treatment for numerous diseases beyond C. difficile infection. Practical considerations for using fecal microbiota transplantation are provided, while it is acknowledged that more high-quality evidence is needed to ascertain the importance of strain specificity in positive treatment outcomes. Because systems biology approaches and synthetic engineering of microbes are now high-throughput and cost-effective, a much wider range of therapeutic possibilities can be explored and vetted. If you are looking for online access to the latest clinical microbiology content, please visit www.wiley.com/learn/clinmicronow. |
| antibody engineering and therapeutics conference: Human Monoclonal Antibodies Michael Steinitz, 2013-09-14 The introduction of monoclonal antibodies revolutionized immunology. The development of human monoclonal antibodies was inspired primarily by the enormous clinical benefits promised by these reagents which can be used as anti-inflammatory reagents, anti-tumor reagents and reagents for passive immunization in a variety of pathologies. Human Monoclonal Antibodies: Methods and Protocols presents technical protocols of cellular and molecular methods for the production, purification and application of human monoclonal antibodies, as well as review articles on related topics of human monoclonal and polyclonal antibodies. Written in the successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and easily accessible, Human Monoclonal Antibodies: Methods and Protocols seeks to serve both professionals and novices with its well-honed methodologies which will prove invaluable in a clinical setting. |
| antibody engineering and therapeutics conference: Cell Culture Engineering Wei-Shu Hu, 2006-08-16 Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent antibody products is the relatively large dose required for effective therapy, demanding larger quantities for the treatment of a given disease. This, coupled with the broadening repertoire of protein drugs, has rapidly expanded the quantity needed for clinical applications. The increasing demand for protein therapeutics has not been met exclusively by construction of new manufacturing plants and increasing total volume capacity. More - portantly the productivity of cell culture processes has been driven upward by an order of magnitude in the past decade. |
| antibody engineering and therapeutics conference: Antibody Engineering Benny K. C. Lo, 2008-02-03 The exquisite binding specificity of antibodies has made them valuable tools from the laboratory to the clinic. Since the description of the murine hybridoma technology by Köhler and Milstein in 1975, a phenomenal number of mo- clonal antibodies have been generated against a diverse array of targets. Some of these have become indispensable reagents in biomedical research, while others were developed for novel therapeutic applications. The attractiveness of an- bodies in this regard is obvious—high target specificity, adaptability to a wide range of disease states, and the potential ability to direct the host’s immune s- tem for a therapeutic response. The initial excitement in finding Paul Ehrlich’s “magic bullet,” however, was met with widespread disappointment when it was demonstrated that murine antibodies frequently elicit the human anti-murine an- body (HAMA) response, thus rendering them ineffective and potentially unsafe in humans. Despite this setback, advances in recombinant DNA techniques over the last 15–20 years have empowered the engineering of recombinant antibodies with desired characteristics, including properties to avoid HAMA. The ability to p- duce bulk quantities of recombinant proteins from bacterial fermentation also fueled the design of numerous creative antibody constructs. To date, the United States Food and Drug Administration has approved more than 10 recombinant antibodies for human use, and hundreds more are in the development pipeline. The recent explosion in genomic and proteomic information appears ready to deliver many more disease targets amenable to antibody-based therapy. |
| antibody engineering and therapeutics conference: Therapeutic Oligonucleotides Jens Kurreck, 2008 This book provides a compelling overall update on current status of RNA interference |
| antibody engineering and therapeutics conference: Monoclonal Antibody Production National Research Council, Institute for Laboratory Animal Research, Committee on Methods of Producing Monoclonal Antibodies, 1999-05-06 The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced. On March 26, 1998, AAVS submitted a second petition, stating that NIH failed to provide valid scientific reasons for not supporting a proposed ban. The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb. In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method. The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop. |
| antibody engineering and therapeutics conference: Antibody Drug Discovery Clive R. Wood, 2012 Antibody-based therapeutics are a central driver of the success of biopharmaceuticals. The discovery technology of this field is isolated to a limited number of centers of excellence in industry and academia. The objective of this volume is to provide a series of guides to those evaluating and preparing to enter particular areas within the field. Each chapter is written with a historical perspective that sets into context the significance of the key developments, and with the provision of “points to consider” for the reader as a value-added feature of the volume. All contributors are experts in their fields and have played pivotal roles in the creation of the technology. |
| antibody engineering and therapeutics conference: Monoclonal Antibodies Vincent Ossipow, Nicolas Fischer, 2016-08-23 Monoclonal Antibodies: Methods and Protocols, Second Edition expands upon the previous edition with current, detailed modern approaches to isolate and characterize monoclonal antibodies against carefully selected epitopes. This edition includes new chapters covering the key steps to generate high quality monoclonals via different methods, from antigen generation to epitope mapping and quality control of the purified IgG. Chapters are divided into four parts corresponding to four distinct objectives. Part I covers monoclonal antibody generation, Part II deals with monoclonal antibody expression and purification, Part III presents methods for monoclonal antibody characterization and modification, and Part IV describes selected applications of monoclonal antibodies. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Monoclonal Antibodies: Methods and Protocols, Second Edition provides crucial initial steps of monoclonal antibody generation and characterization with state-of-the art protocols. |
| antibody engineering and therapeutics conference: Antibody Fc Margaret Ackerman, Falk Nimmerjahn, 2013-08-06 Antibody Fc is the first single text to synthesize the literature on the mechanisms underlying the dramatic variability of antibodies to influence the immune response. The book demonstrates the importance of the Fc domain, including protective mechanisms, effector cell types, genetic data, and variability in Fc domain function. This volume is a critical single-source reference for researchers in vaccine discovery, immunologists, microbiologists, oncologists and protein engineers as well as graduate students in immunology and vaccinology. Antibodies represent the correlate of protection for numerous vaccines and are the most rapidly growing class of drugs, with applications ranging from cancer and infectious disease to autoimmunity. Researchers have long understood the variable domain of antibodies, which are responsible for antigen recognition, and can provide protection by blocking the function of their target antigen. However, recent developments in our understanding of the protection mediated by antibodies have highlighted the critical nature of the antibody constant, or Fc domain, in the biological activity of antibodies. The Fc domain allows antibodies to link the adaptive and innate immune systems, providing specificity to a wide range of innate effector cells. In addition, they provide a feedback loop to regulate the character of the immune response via interactions with B cells and antigen-presenting cells. - Clarifies the different mechanisms of IgG activity at the level of the different model systems used, including human genetic, mouse, and in vitro - Covers the role of antibodies in cancer, infectious disease, and autoimmunity and in the setting of monoclonal antibody therapy as well as naturally raised antibodies - Color illustrations enhance explanations of the immune system |
| antibody engineering and therapeutics conference: Cell Press Reviews: Cancer Therapeutics Cell Press, 2013-12-10 Cell Press Reviews: Cancer Therapeutics informs, inspires, and connects cancer researchers at all stages in their careers with timely, comprehensive reviews written by leaders in the field and curated by Cell Press editors. The publicatio offers a broad view of some of the most compelling topics in cancer therapeutics including: - Genetic approaches for personal oncology - Targeting epigenetic dysregulation and protein interaction networks - Vaccines and antibodies in cancer immunotherapy - Tumor heterogeneity and chemotherapy resistance - Tumor associated macrophages in anticancer treatment Contributions come from leading voices in the field, including: - Daniel A. Haber, Director of Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School - Tony Kouzarides, Professor at the University of Cambridge, Deputy Director of the Wellcome Trust/Cancer Research UK Gurdon Institute, and a founder of the cancer drug discovery company Chroma Therapeutics - Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, President of the American Association for Cancer Research, member of the presidentially appointed National Cancer Advisory Board, and recipient of the 2013 Breakthrough Prize in Life Sciences Cell Press Reviews: Cancer Therapeutics is part of the Cell Press Reviews series, which features reviews published in Cell Press primary research and Trends reviews journals. - Provides timely, comprehensive articles on a wide range of topics in cancer therapeutics - Offers insight from experts on genetic, molecular, and cellular aspects of cancer therapy - Features reviews on basic science advances translated into drug discovery and therapeutic approaches - Includes articles originally published in Cell, Cancer Cell, Trends in Genetics, Trends in Molecular Medicine, and Trends in Pharmacological Sciences |
| antibody engineering and therapeutics conference: Predictive Toxicology Christoph Helma, 2005-03-17 A comprehensive overview of techniques and systems currently utilized in predictive toxicology, this reference presents an in-depth survey of strategies, algorithms, and prediction methods to select, calculate, and represent the features and properties of chemical structures in biological systems. It provides sources of high-quality toxicity data, the most important commercial and noncommercial predictive toxicology programs, and advanced technologies in computational chemistry, biology, statistics, and data mining. Predictive Toxicology explores applications that go beyond classical structure-activity relationships and discusses programs such as OncoLogic, META, MC4PC, PASS, and lazar. |
| antibody engineering and therapeutics conference: Cancer and IgE Manuel L. Penichet, Erika Jensen-Jarolim, 2010-01-23 Erika Jensen-Jarolim and Manuel L. Penichet 1. 1 Background Infectious diseases, being the major burden in the history of mankind worldwide th until the beginning of the 20 century, were important triggers in the understanding of immunological mechanisms. In contrast to infectious diseases, reports of all- gies and cancers were less common, but increased tremendously within the last century. Based on the US mortality data of the National Center for Health Statistics, Centers for Disease Control and Prevention 2009, a recent report from the American Cancer Society indicated that the number of cancer deaths increased approximately from 100,000 to 550,000 per year between 1930 and 2006, paralleling the increase of the total population during this period. Leading causes of death from cancer are lung and bronchus cancer, in men prostate cancer, and in women breast c- cer [1, 2]. Normalization to population size shows that the cancer death rate for most malignancies has been generally stable, although the mortality rate of certain malignancies, such as lung and bronchus cancer, has increased over the last 50 years [1-3]. In allergy, the situation is less clear, because for the time period around the turn of th the 19 century, only imprecise information is available. However, within the last 30 years the incidences of allergies has doubled not only in industrial countries, but in developing countries as well [4]. |
| antibody engineering and therapeutics conference: Development of Antibody-Based Therapeutics Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp, 2018-09-11 With a key focus on recent developments and advances in the field, this book provides in-depth coverage of topics fundamental to the development of targeted therapeutics. The expansion of targeted modalities in rapidly evolving therapeutic areas, such as immune-oncology, and developments with respect to combination therapies, novel technologies, and the therapeutic application of antibody-drug conjugates, are presented. Additionally, the book builds upon topics discussed in the first edition (2012) where recent innovations warrant elaboration. This, the second edition of Development of Antibody-Based Therapeutics: Translational Considerations, represents a comprehensive evaluation of progress in the field, which sits alongside the first edition to inform, in detail, professional and academic researchers, as well as graduate students. |
| antibody engineering and therapeutics conference: Systems and Synthetic Immunology Shailza Singh, 2021-04-25 Systems and Synthetic Immunology focuses on the similarities between biology and engineering at the systems level, which are important for applying engineering theories to biology problems. With the advent of new genomic techniques, there are numerous systematic investigations underway in the scientific world. This volume highlights techniques that can be used to effectively combine two of the most essential biological fields - Systems Biology and Synthetic Immunology. The respective chapters discuss the role of synthetic immunology in biotechnology, production of biomaterials, and their use in vaccine delivery. Further topics include the importance of cytokines; the use of genomic engineering tools in immunotherapy; immunosensors; nanotherapeutics; and bioinformatics tools in biomedical applications. Given its scope, the book offers readers an up-to-date and comprehensive review of this unique and dynamic field of research. |
| antibody engineering and therapeutics conference: Handbook of Therapeutic Antibodies Stefan Dübel, Janice M. Reichert, 2014-12-03 Dieses Nachschlagewerk zu therapeutischen Antikörpern sucht auch in der komplett überarbeiteten 2. Auflage seinesgleichen und bietet 30 % neue Inhalte zu Entwicklung, Herstellung und therapeutischen Anwendungen dieser Biomoleküle. |
| antibody engineering and therapeutics conference: Evolution of Translational Omics Institute of Medicine, Board on Health Sciences Policy, Board on Health Care Services, Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, 2012-09-13 Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials. |
| antibody engineering and therapeutics conference: Pharmaceutical Biotechnology Daan J. A. Crommelin, Robert D. Sindelar, 2002-11-14 The field of pharmaceutical biotechnology is evolving rapidly. A whole new arsenal of protein pharmaceuticals is being produced by recombinant techniques for cancer, viral infections, cardiovascular and hereditary disorders, and other diseases. In addition, scientists are confronted with new technologies such as polymerase chain reactions, combinatorial chemistry and gene therapy. This introductory textbook provides extensive coverage of both the basic science and the applications of biotechnology-produced pharmaceuticals, with special emphasis on their clinical use. Pharmaceutical Biotechnology serves as a complete one-stop source for undergraduate pharmacists, and it is valuable for researchers and professionals in the pharmaceutical industry as well. |
| antibody engineering and therapeutics conference: Anaphylaxis and Hypersensitivity Reactions Mariana C. Castells, 2010-12-09 Despite wide recognition as a serious public health problem, anaphylaxis and hypersensitivity reactions remain under-recognized and under-diagnosed. This book fills the gaps in our understanding of the identification of triggers, recognition of clinical presentations, understanding of the natural history of these reactions, and selection of treatment strategies including those focused on cellular and molecular targets. The book provides a detailed examination of disease etiology, pathogenesis, and pathophysiology and their correlation to clinical practice. Forefront knowledge of the mediators and mechanisms of anaphylaxis is covered with an emphasis on how new discoveries shape our current and emerging therapies. |
| antibody engineering and therapeutics conference: Toxicokinetics , 1995 |
| antibody engineering and therapeutics conference: Modern Multidimensional Scaling Ingwer Borg, Patrick Groenen, 2013-04-18 Multidimensional scaling (MDS) is a technique for the analysis of similarity or dissimilarity data on a set of objects. Such data may be intercorrelations of test items, ratings of similarity on political candidates, or trade indices for a set of countries. MDS attempts to model such data as distances among points in a geometric space. The main reason for doing this is that one wants a graphical display of the structure of the data, one that is much easier to understand than an array of numbers and, moreover, one that displays the essential information in the data, smoothing out noise. There are numerous varieties of MDS. Some facets for distinguishing among them are the particular type of geometry into which one wants to map the data, the mapping function, the algorithms used to find an optimal data representation, the treatment of statistical error in the models, or the possibility to represent not just one but several similarity matrices at the same time. Other facets relate to the different purposes for which MDS has been used, to various ways of looking at or interpreting an MDS representation, or to differences in the data required for the particular models. In this book, we give a fairly comprehensive presentation of MDS. For the reader with applied interests only, the first six chapters of Part I should be sufficient. They explain the basic notions of ordinary MDS, with an emphasis on how MDS can be helpful in answering substantive questions. |
| antibody engineering and therapeutics conference: Aggregation of Therapeutic Proteins Wei Wang, Christopher J. Roberts, 2010-12-28 This book gives pharmaceutical scientists an up-to-date resource on protein aggregation and its consequences, and available methods to control or slow down the aggregation process. While significant progress has been made in the past decade, the current understanding of protein aggregation and its consequences is still immature. Prevention or even moderate inhibition of protein aggregation has been mostly experimental. The knowledge in this book can greatly help pharmaceutical scientists in the development of therapeutic proteins, and also instigate further scientific investigations in this area. This book fills such a need by providing an overview on the causes, consequences, characterization, and control of the aggregation of therapeutic proteins. |
| antibody engineering and therapeutics conference: Introduction to Pharmaceutical Biotechnology, Volume 1 (Second Edition): Basic Techniques and Concepts , 2024-11 |
December 15-18, 2024 San Diego, CA - Informa
Informa Connect’s Antibody Engineering & Therapeutics conference offers a unique opportunity to reach researchers working in this important field of science from both industry and academic …
Antibody Engineering & Therapeutics Conference
Antibody Engineering & Therapeutics Conference December 7th 2022 Next-generation immunotherapies to address cancer immune resistance KVA12123 a VISTA Blocking …
THE #1 ANTIBODY ENGINEERING CONFERENCE FOR …
Prepare for main Antibody Engineering & Therapeutics conference on December 14-16, by attending this highly popular training course the week before, which will give
Antibody Engineering & Therapeutics 2021: The Rewind
In December 2021, theAntibody Engineering & Therapeutics hybrid conference took place in San Diego, with a digital experience option for those who couldn't join. Sessions exploring topics …
SESSIONS Antibody Engineering & Therapeutics US PRE …
Here, I will present and discuss some approaches to generate antigen-specific antibodies, including their pros and cons. Using next-generation antigen barcoding and the 10x Genomics …
Antibody Engineering & Therapeutics Virtual 2020: Post-event …
The conference was largely focused on COVID-19 antibodies, elaborating on the talks from the Antibody Engineering & Therapeutics Virtual Event held in summer 2020. The focus of this …
Antibody Engineering & Therapeutics Asia Location
Antibody Engineering & Therapeutics Asia Date: October 21 – 23, 2024 Location: The Westin Miyako Kyoto Participation fee: Contact: Felicity Bell, Informa Connect Life Sciences E-mail: …
2025 Antibodies and Complement meeting: B cells, …
On May 29, 2025 (day 4), the morning session is dedicated to AI and novel approaches for improving antibodies and complement drugs. All participants will share lunch. We will hold …
Antibody Engineering & Therapeutics Series 2024 …
preview of our in-person conference Antibody Engineering & Therapeutics Asia, scheduled for October 21-23 in Kyoto, Japan! Don’t miss the opportunity to engage your top prospects with a …
Asia’s Leading Conference To Accelerate Antibody/Protein …
The course will focus on the engineering and enhancement of antibodies and antibody-like scaffolds. Examples will include work on antibody fragment affinity improvement by 100-fold to …
Antibody engineering and therapeutics conference - Taylor
The 25th anniversary of the Antibody Engineering & Therapeutics Conference, the Annual Meeting of The Antibody Society, will be held in Huntington Beach, CA, December 7–11, 2014. …
Antibody engineering and therapeutics, the annual meeting …
The 26th Antibody Engineering & Therapeutics meeting, the annual meeting of The Antibody Society united over 800 participants from all over the world in San Diego from 6–10 December …
Novel IgG1 Cysteine Insertion Sites Enable Site-Specific
•Engineering antibodies to include cysteine residue insertions allow for site-specific (SS) conjugation to thiol reactive small molecules to generate antibody drug conjugates (ADCs).1 …
Antibody Engineering
Fast-track your antibody research to the clinic and beyond by collaborating with leading pharma, biotechs, academia and solution providers from North America, Asia and Europe. 125+ …
The Essential Protein & Antibody Engineering Summit
ELEVATE YOUR PROTEIN & ANTIBODY ENGINEERING RESEARCH. CONFERENCE AT-A-GLANCE.
Antibody Engineering & Therapeutics Asia 2024: A Premier …
Join over 250 experts in Kyoto this October to explore the latest breakthroughs in antibody engineering, AI-guided discovery, and therapeutic advancements.
To build your custom sponsorship package, contact: Blake
32nd year, this event is the longest running conference dedicated to current developments in the basic science of antibody engineering and therapeutics. By sponsoring this year you’ll also get …
Antibody Engineering & Therapeutics Europe 2024 …
Engage key decision makers seeking technologies and partnerships to accelerate next generation antibodies towards commercial success. Informa Connect’s Antibody Engineering & …
ANB032, a BTLA Checkpoint Agonist Monoclonal Antibody
Hsu et al. Presented at the Antibody Engineering & Therapeutics Conference US, San Diego, Dec 12-16, 2021 ANB032 Reduced Th1, Th2, Th17 and Th22 Cytokine Secretion in AD Patient …
Antibody Engineering & Therapeutics 2023 Sponsorship …
The Antibody Engineering & Therapeutics event series and digital portfolio is the most comprehensive series of events and programs brining the latest science, technologies, and …
SESSIONS Antibody Engineering & Therapeutics US PRE …
(MuSK) antibody, derived from the SIMPLE© antibody platform, with broad potential in neuromuscular diseases. Congenital myasthenia (CM) is a devastating neuromuscular …
Antibody Engineering & Therapeutics Virtual 2020: Post …
The conference was largely focused on COVID-19 antibodies, elaborating on the talks from the Antibody Engineering & Therapeutics Virtual Event held in summer 2020. The focus of this …
Antibody Engineering & Therapeutics 2021: The Rewind
In December 2021, theAntibody Engineering & Therapeutics hybrid conference took place in San Diego, with a digital experience option for those who couldn't join. Sessions exploring topics …
BISPECIFIC ANTIBODY ENGINEERING AND …
therapeutics. Emicizumab is a FDA approved bispecific antibody for the treatment of haemophilia A, that bridges the clotting factors IX and X, and restores a functional blood-clotting cascade in …
Post-Event Antibody - Informa Connect
antibody engineering and therapeutics industry in 2020 were explored. From antibody discovery and developability, to advances in the latest technologies such as computational and machine …
EXHIBITOR MANUAL SUMMARY QUICK LINKS GES
There are many contractors for Antibody Engineering & Therapeutics please see a breakdown with links of where to go for relevant information: GES - Booth Furnishings, Shipping …
Liability & Insurance
and personal injury, naming Informa onnect, an Informa company Antibody Engineering & Therapeutics US, Marriott Marquis San Diego, and GES as additionally insured, must be …
EXHIBITOR MANUAL SUMMARY - Informa Connect
There are many contractors for Antibody Engineering & Therapeutics please see a breakdown with links of where to go for relevant information: GES - Booth Furnishings, Shipping …
Liability & Insurance - Informa Connect
Antibody Engineering & Therapeutics US), Marriott Marquis San Diego, and . GES as additionally insured, must be obtained by the exhibitor at his/ her own expense. All exhibiting companies …
Fc engineering for improved developability and retained …
Dec 11, 2017 · The value of Fc engineering •Engineered Fc variants compose a powerful toolbox for adding value and differentiation to subsequent generations of therapeutic antibodies and Fc …
